Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tongjitang Chinese Medicines Buyout Update

publication date: Aug 19, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tongjitang Chinese Medicines Company reported that it is still considering the buyout offer from a JV comprised of its Chairman/CEO and Fosun Industrial, the Hong Kong conglomerate. The JV offered $4.50 per ADS on April 8, 2010 for every share its members do not already own. Mr. Xiaochun Wang, Tongjitang’s Chairman and CEO, now has a 51% stake in the company and Fosun owns an additional 32%. Tongjitang is currently trading hands at around $3.50 per share, a 22% discount to the current offer. More details....

Stock Symbol: (NYSE: TCM)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...